Imatinib and polypharmacy in very old patients with chronic myeloid leukemia: effects on response rate, toxicity and outcome

BACKGROUND: About 40% of all patients with chronic myeloid leukemia are currently old or very old. They are effectively treated with imatinib, even though underrepresented in clinical studies. Furthermore, as it happens in the general population, they often receive multiple drugs for associated chro...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Oncotarget
Main Authors: Iurlo, Alessandra, Nobili, Alessandro, Latagliata, Roberto, Bucelli, Cristina, Castagnetti, Fausto, Breccia, Massimo, Abruzzese, Elisabetta, Cattaneo, Daniele, Fava, Carmen, Ferrero, Dario, Gozzini, Antonella, Bonifacio, Massimiliano, Tiribelli, Mario, Pregno, Patrizia, Stagno, Fabio, Vigneri, Paolo, Annunziata, Mario, Cavazzini, Francesco, Binotto, Gianni, Mansueto, Giovanna, Russo, Sabina, Falzetti, Franca, Montefusco, Enrico, Gugliotta, Gabriele, Storti, Sergio, D'Addosio, Ada M., Scaffidi, Luigi, Cortesi, Laura, Cedrone, Michele, Rossi, Antonella Russo, Avanzini, Paolo, Mauro, Endri, Spadea, Antonio, Celesti, Francesca, Giglio, Gianfranco, Isidori, Alessandro, Crugnola, Monica, Calistri, Elisabetta, Sorà, Federica, Rege-Cambrin, Giovanna, Sica, Simona, Luciano, Luigiana, Galimberti, Sara, Orlandi, Ester M., Bocchia, Monica, Tettamanti, Mauro, Alimena, Giuliana, Saglio, Giuseppe, Rosti, Gianantonio, Mannucci, Pier Mannuccio, Cortelezzi, Agostino
Formato: Artigo
Idioma:Inglês
Publicado em: Impact Journals LLC 2016
Assuntos:
Clinical Research Paper
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5346773/
https://ncbi.nlm.nih.gov/pubmed/27579540
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.11657
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados